Versartis is developing new therapeutic proteins utilizing the novel half-life extension technology, XTEN.
Jun 26 2010 Versartis Data for Type 2 Diabetes Drug VRS-859 (exenatide-XTEN) Featured at American Diabetes Association Annual Scientific Meeting
Jun 22 2010 Versartis Initiates First Clinical Trial for New Diabetes Drug VRS-859 (exenatide-XTEN)
Jun 20 2010 Versartis Presents Results of Three Studies at ENDO 2010
The company is interested in exploring partnerships on our products to accelerate the development process and ensure successful commercialization.
